Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer DB Segment — Biopharma Pretax Income by Year
DB Segment — Biopharma Pretax Income ($M) ($M)
Pfizer DB Segment — Biopharma Pretax Income: $29,342M in FY2025, up 4.9% from a year earlier.
Latest, FY2025
29,342
Period ended Dec 31, 2025
Change on a year earlier
+4.9%
27,969 in FY2024
History
9 years
Since FY2017
Sources
5
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Database (SEC Form 10-K / 10-Q XBRL via lib/db.py).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | DB Segment — Biopharma Pretax Income ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29,342 | +4.9% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 27,969 | +77.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 15,767 | -67.1% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 47,939 | +17.9% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 40,647 | +49.5% | Form 10-K (filed 2023-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 27,191 | +11.4% | Form 10-K (filed 2023-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 24,419 | +2.9% | Form 10-K (filed 2022-02-24) ↗ |
| FY2018 | Dec 31, 2018 | 23,738 | +7.0% | Form 10-K (filed 2020-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 22,194 | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer DB Segment — Biopharma Pretax Income ($M), annual FY2017–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/db-seg-ebt-bio
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.